does tirzepatide cause heart racing Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats How the weight loss drug

Tirzepatide and Semaglutide are both highly effective GLP-1 medications for weight loss, but Tirzepatide is a dual GIP/GLP-1 receptor co-agonist

Subcutaneous administration (which bypasses first-pass metabolism and delivers more peptide to target tissues) was not extensively tested in human trials, and this route is what most current research protocols use

10.1208/s12249-009-9264-8 268 YadavA

Approximately 30-40% of semaglutide users experience mild to moderate nausea in the first 2-4 weeks, with severity correlating to individual genetic sensitivity rather than meal size

However, potential pitfalls may arise in the conversion process